Johnson & Johnson (JNJ) news
Recent news
J&J's Tremfay hits 94% clinical remission at 3 years
AInvest Wire · 7h agoJ&J - At week 112, 72% achieve PASI 90, 70% achieve IGA 0/1 with icotyde
AInvest Wire · 3d agoMLB Concept stocks rose in regular trading, with JNJ gaining 1.62%.
Johnson & Johnson (JNJ) closed the latest trading session up 1.62%, bucking the broader trend of its recent underperformance. This rise contrasts with its previous month's decline of 6.98%, which outpaced the Medical sector's loss of 3.74% and the S&P 500's modest gain of 0.55% . The stock's…
AInvest Wire · 5d agoJ&J - ICOTYDE-treated patients show 70% clear or almost clear skin at week 112
AInvest Wire · Oct 2, 2026J&J - 60% scalp psoriasis, 89% genital psoriasis patients achieve complete clearance at week 112
Johnson & Johnson (NYSE: JNJ) has reported updated results from its Phase 3 ICONIC-TOTAL study of icotrokinra, a first-in-class investigational targeted oral peptide that blocks the IL-23 receptor, in patients with plaque psoriasis affecting high-impact sites. The data, presented at the 2025 Fall…
AInvest Wire · Oct 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.